Australia markets close in 3 hours 43 minutes

SAVA Jan 2025 30.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
6.00-0.40 (-6.25%)
As of 03:59PM EST. Market open.
Full screen
Previous close6.40
Open6.00
Bid5.50
Ask6.25
Strike30.00
Expiry date2025-01-17
Day's range6.00 - 6.00
Contract rangeN/A
Volume1
Open interest504
  • GlobeNewswire

    Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

    AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024. Presentation details Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 T

  • GuruFocus.com

    Cassava Sciences Inc (SAVA) Reports Full-Year 2023 Financial Results

    Key Financials and Corporate Updates Highlighted

  • GlobeNewswire

    Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

    $121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies.Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Company. AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: